Altogether our data suggest ERK1/2 inhibitors might be able to exert therapeutic benefit to EOC patients by regulating the autophagic flux in the tumor cells particularly after few cycles of platinum–taxol therapy, which is known to initiate resistance development. This evidence concerns the gene MAPK3 and neoplasm.